A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
ANAVEX LIFE SCIENCES CORP.
AVXL
$206M
Mkt Cap
$2.40
-3.23%
ANAVEX LIFE SCIENCES CORP. (AVXL) has a 5-year average return on invested capital (ROIC) of -37.7%. This is below average and may indicate limited pricing power.
ANAVEX LIFE SCIENCES CORP. (AVXL) has a market capitalization of $222M. It is classified as a small-cap stock.
ANAVEX LIFE SCIENCES CORP. (AVXL) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 5.07%.
ANAVEX LIFE SCIENCES CORP. (AVXL) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ANAVEX LIFE SCIENCES CORP. (AVXL) generated $-39 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ANAVEX LIFE SCIENCES CORP. (AVXL) has a debt-to-equity ratio of 0.09. This indicates a conservatively financed balance sheet.
ANAVEX LIFE SCIENCES CORP. (AVXL) reported earnings per share (EPS) of $-0.54 in its most recent fiscal year.
Overview and Strategy Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials. The Company’s focus is on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Our research and development pipeline includes ANAVEX®2-73 currently in three different clinical trial indications, and ANAVEX®3-71 currently in one clinical trial and several other compounds in different stages of clinical and pre-clinical development.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.4M | - | - | - | - | - |
| Net Income | -40M | -46M | -43M | -48M | -48M | -38M |
| EPS | $-0.46 | $-0.54 | $-0.52 | $-0.60 | $-0.58 | $-0.54 |
| Free Cash Flow | 0 | -39M | -31M | -28M | -24M | -30M |
| ROIC | -26.5% | -43.1% | -35.8% | -33.5% | -33.7% | -42.6% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.09 | 0.13 | 0.09 | 0.07 | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -45M | -51M | -53M | -56M | -51M | -42M |
| Operating Margin | -1022.2% | - | - | - | - | - |
| ROE | -31.5% | -43.1% | -35.8% | -33.5% | -33.7% | -42.6% |
| Shares Outstanding | 93M | 86M | 83M | 79M | 82M | 70M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.4M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 732K | 2.3M | 7.3M | 11M | 13M | 22M | 25M | 33M | 38M | 44M | 42M | 38M | 32M |
| SG&A | 1.0M | 2.7M | 8.3M | 5.0M | 6.0M | 6.8M | 5.9M | 9.0M | 13M | 12M | 11M | 14M | 13M |
| EBIT | -3.0M | -16M | -15M | -13M | -17M | -26M | -31M | -42M | -51M | -56M | -53M | -51M | -45M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1022.2% |
| Net Income | -10.0M | -12M | -15M | -13M | -17M | -26M | -26M | -38M | -48M | -48M | -43M | -46M | -40M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -915.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -31.9% | -82.5% | -122.2% | -88.1% | -77.1% | -129.0% | -110.6% | -42.6% | -33.7% | -33.5% | -35.8% | -43.1% | -26.5% |
| ROE | -5175.0% | -186.3% | -154.2% | -88.1% | -77.1% | -129.0% | -110.6% | -42.6% | -33.7% | -33.5% | -35.8% | -43.1% | -31.5% |
| ROA | -257.3% | -106.1% | -118.0% | -72.1% | -66.1% | -105.8% | -87.8% | -38.7% | -31.4% | -30.8% | -31.7% | -38.7% | -30.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -2.7M | -4.2M | -9.2M | -9.0M | -13M | -19M | -21M | -30M | -24M | -28M | -31M | -39M | -34M |
| Free Cash Flow | -2.7M | -4.2M | -9.2M | -9.0M | -13M | -19M | -21M | -30M | -24M | -28M | -31M | -39M | 0 |
| Owner Earnings | -3.3M | -5.9M | -14M | -13M | -18M | -25M | -26M | -39M | -43M | -44M | -40M | -51M | -45M |
| CapEx | 3K | 3K | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 0 | 0 | 1K | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | 2K | 2K | 2K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 0 | 0 | 1K | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 21M | 24M | 24M | 28M | 11M | 11M | 11M |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 5.1% |
| Stock-Based Comp | 638K | 1.6M | 5.1M | 4.1M | 5.5M | 6.4M | 4.9M | 8.2M | 18M | 16M | 9.4M | 12M | 11M |
| Debt Repayment | 0 | 0 | 0 | 0 | 101K | 50K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -7.1M | -15M | -9.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -263M |
| Cash & Equiv. | 7.3M | 15M | 9.2M | 27M | 23M | 22M | 29M | 152M | 149M | 151M | 132M | 103M | 263M |
| Long-Term Debt | N/A | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 1.00 | 0.01 | 0.01 | 0.15 | 0.19 | 0.25 | 0.27 | 0.07 | 0.07 | 0.09 | 0.13 | 0.09 | 0.00 |
| Interest Coverage | -418.8 | -224.9 | -1298.0 | -151.1 | -66.3 | -125.5 | -172.7 | -1599.4 | -53.8 | -8.6 | -7.2 | -11.0 | -11.0 |
| Equity | 193K | 13M | 6.3M | 24M | 20M | 20M | 27M | 151M | 142M | 142M | 120M | 95M | 127M |
| Total Assets | 7.4M | 15M | 9.5M | 28M | 24M | 25M | 35M | 162M | 153M | 154M | 136M | 104M | 133M |
| Total Liabilities | 7.2M | 2.7M | 3.2M | 3.6M | 3.9M | 5.0M | 7.3M | 11M | 10M | 13M | 15M | 8.9M | 6.4M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | -63M | -78M | -91M | -109M | -133M | -160M | -198M | -246M | -293M | -336M | -382M | -388M |
| Working Capital | 5.9M | 13M | 6.3M | N/A | 20M | 20M | N/A | N/A | N/A | N/A | N/A | N/A | -2.5M |
| Current Assets | 7.4M | 15M | 9.4M | 28M | 24M | 25M | N/A | N/A | N/A | N/A | N/A | N/A | 396K |
| Current Liabilities | 1.4M | 2.7M | 3.2M | N/A | 3.9M | 5.0M | N/A | N/A | 5.9M | 7.3M | 4.8M | 3.9M | 2.9M |
| Per Share Data | |||||||||||||
| EPS | -4.08 | -2.60 | -0.42 | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.58 | -0.60 | -0.52 | -0.54 | -0.46 |
| Owner EPS | -0.24 | -1.26 | -0.41 | -0.32 | -0.41 | -0.51 | -0.45 | -0.55 | -0.52 | -0.56 | -0.49 | -0.59 | -0.48 |
| Book Value | 0.01 | 2.75 | 0.18 | 0.59 | 0.46 | 0.42 | 0.47 | 2.15 | 1.74 | 1.79 | 1.45 | 1.10 | 1.37 |
| Cash Flow/Share | -0.19 | -0.91 | -0.26 | -0.22 | -0.28 | -0.38 | -0.36 | -0.43 | -0.30 | -0.35 | -0.37 | -0.45 | -0.43 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 13.7M | 4.7M | 35.1M | 40.8M | 44.2M | 48.7M | 58.4M | 70.2M | 82.1M | 79.2M | 82.7M | 85.9M | 92.7M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | 5.4 | 8.0 | 13.0 | 9.5 | 6.0 | 3.8 | 3.9 | 7.8 | 1.8 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 51.0 |
| FCF Yield | N/A | N/A | N/A | N/A | -10.4% | -11.4% | -6.0% | -2.1% | -2.8% | -5.2% | -6.6% | -5.2% | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 121M | 163M | 354M | 1.4B | 858M | 532M | 470M | 744M | 222M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 3.09 | 2.67 | 3.55 | 12.74 | 12.86 | 9.30 | 5.58 | 8.95 | 2.40 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 2.73 | 3.34 | 4.66 | 18.41 | 10.45 | 6.72 | 5.68 | 8.66 | 2.40 |
ANAVEX LIFE SCIENCES CORP. passes 1 of 9 quality checks, indicating weak fundamentals.
Total shareholder yield (buybacks) is 5.1%.
ANAVEX LIFE SCIENCES CORP. (AVXL) has a return on equity (ROE) of -43.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for ANAVEX LIFE SCIENCES CORP. (AVXL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ANAVEX LIFE SCIENCES CORP. (AVXL) has a book value per share of $1.10, based on its most recent annual SEC filing.